The Role of Selenium-Binding Protein 1 in Ulcerative Colitis
Author Information
Author(s): Gabriela Fonseca-Camarillo, Janette Furuzawa-Carballeda, Ángel A. Priego-Ranero, Rafael Barreto-Zúñiga, Braulio Martínez-Benítez, Jesús K. Yamamoto-Furusho
Primary Institution: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Hypothesis
The study aimed to determine the clinical outcome of SELENBP1 expression in colonic tissue from patients with ulcerative colitis (UC).
Conclusion
The upregulation of SELENBP1 was associated with a more benign clinical course of ulcerative colitis.
Supporting Evidence
- SELENBP1 gene expression was significantly lower in patients with active UC than those in remission.
- Overexpression of SELENBP1 was associated with a more benign clinical course.
- SELENBP1-positive cells were found mainly in the submucosa’s inflammatory infiltrate.
Takeaway
This study found that a protein called SELENBP1 helps patients with ulcerative colitis feel better and stay healthy longer.
Methodology
The study analyzed SELENBP1 mRNA expression in 34 patients with UC and 20 controls using statistical analyses with SPSS 19.
Limitations
The study is limited to the Mexican population and further studies in other populations are needed.
Participant Demographics
The study included 34 patients with ulcerative colitis (17 active and 17 in remission) and 20 controls without intestinal inflammation.
Statistical Information
P-Value
p = 0.003
Confidence Interval
95% CI: 1.00–1.41
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website